Storia in 8 fonti

India pharma market enters US tariff transition with strong domestic growth: Report

Indian Pharmaceutical Market (IPM) posted its strongest monthly performance in more than two years in June, with 16 per cent y-o-y growth, while first-quarter FY27 growth accelerated to 13.5%

Raccontata da

hindustantimes.com

economictimes.indiatimes.com

timesofindia.indiatimes.com

newsbytesapp.com

thehindubusinessline.com

theprint.in

asia.nikkei.com

zerohedge.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo1 g fa

India pharma market enters US tariff transition with strong domestic growth: Report

Indian Pharmaceutical Market (IPM) posted its strongest monthly performance in more than two years in June, with 16 per cent y-o-y growth, while first-quarter FY27 growth accelerated to 13.5%

originale

Timeline cronologica

mercoledì 22 luglio 2026·hindustantimes.com
0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines
In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News
mercoledì 22 luglio 2026·economictimes.indiatimes.com
Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028

Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption…

India pharma market enters US tariff transition with strong domestic growth: Report

Confronto fonti

India pharma market enters US tariff transition with strong domestic growth: Report

Timeline cronologica

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

Pharma companies in a flux over Trump's 200% tariff move on generics

Trump's generic drugs tariff threatens Indian pharma's top market

0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit India

Trump threatens tariff on generic medicines: Should India be worried?

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

Trump’s proposed generic drug tariffs ‘not practical’, says Indian pharma; US consumers will pay the price

0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India

Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Trump’s 100% generic drug duty threatens US low-cost supply

200% Trump tariff shock? India’s cheap pills may still beat US rivals

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

US proposal to impose steep tariffs on generic medicines could significantly impact India: GTRI

Trump's generic drugs tariff threatens Indian pharma's top market

UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners

US tariffs could raise drug prices, squeeze Indian generics

Pharma companies in a flux over Trump's 200% tariff move on generics